Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SiRNA delivery with exosome nanoparticles.
van den Boorn JG, Schlee M, Coch C, Hartmann G. van den Boorn JG, et al. Nat Biotechnol. 2011 Apr;29(4):325-6. doi: 10.1038/nbt.1830. Nat Biotechnol. 2011. PMID: 21478846 No abstract available.
Nucleic acid adjuvants: toward an educated vaccine.
van den Boorn JG, Barchet W, Hartmann G. van den Boorn JG, et al. Adv Immunol. 2012;114:1-32. doi: 10.1016/B978-0-12-396548-6.00001-9. Adv Immunol. 2012. PMID: 22449776 Review.
Exosomes as nucleic acid nanocarriers.
van den Boorn JG, Dassler J, Coch C, Schlee M, Hartmann G. van den Boorn JG, et al. Adv Drug Deliv Rev. 2013 Mar;65(3):331-5. doi: 10.1016/j.addr.2012.06.011. Epub 2012 Jun 28. Adv Drug Deliv Rev. 2013. PMID: 22750807 Review.
Inflammasome-Dependent Induction of Adaptive NK Cell Memory.
van den Boorn JG, Jakobs C, Hagen C, Renn M, Luiten RM, Melief CJ, Tüting T, Garbi N, Hartmann G, Hornung V. van den Boorn JG, et al. Immunity. 2016 Jun 21;44(6):1406-21. doi: 10.1016/j.immuni.2016.05.008. Epub 2016 Jun 7. Immunity. 2016. PMID: 27287410 Free article.
RIG-I activation induces the release of extracellular vesicles with antitumor activity.
Daßler-Plenker J, Reiners KS, van den Boorn JG, Hansen HP, Putschli B, Barnert S, Schuberth-Wagner C, Schubert R, Tüting T, Hallek M, Schlee M, Hartmann G, Pogge von Strandmann E, Coch C. Daßler-Plenker J, et al. Among authors: van den boorn jg. Oncoimmunology. 2016 Aug 19;5(10):e1219827. doi: 10.1080/2162402X.2016.1219827. eCollection 2016. Oncoimmunology. 2016. PMID: 27853642 Free PMC article.
RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation.
Engel C, Brügmann G, Lambing S, Mühlenbeck LH, Marx S, Hagen C, Horváth D, Goldeck M, Ludwig J, Herzner AM, Drijfhout JW, Wenzel D, Coch C, Tüting T, Schlee M, Hornung V, Hartmann G, Van den Boorn JG. Engel C, et al. Among authors: van den boorn jg. Cancer Immunol Res. 2017 Jun;5(6):455-467. doi: 10.1158/2326-6066.CIR-16-0129-T. Epub 2017 May 3. Cancer Immunol Res. 2017. PMID: 28468914
RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma.
Lambing S, Tan YP, Vasileiadou P, Holdenrieder S, Müller P, Hagen C, Garbe S, Behrendt R, Schlee M, van den Boorn JG, Bartok E, Renn M, Hartmann G. Lambing S, et al. Among authors: van den boorn jg. J Mol Cell Biol. 2023 Jun 1;15(1):mjad001. doi: 10.1093/jmcb/mjad001. J Mol Cell Biol. 2023. PMID: 36626927 Free PMC article.
17 results